Diabetes Clinical Research Currently Recruiting

A Phase II, randomized, parallel group, dose-finding study of subcutaneously administered BI 456906 for 16 weeks, compared with placebo and open-label semaglutide in patients with type 2 diabetes mellitus

You are eligible if you:

  • are aged between 18 and 75 years old
  • have had a diagnosis of Type 2 Diabetes for more than 6 months
  • have raised blood sugar levels
  • are overweight
  • are taking only a stable dose of Metformin to treat your Type 2 Diabetes (you can be taking medication to treat other medical conditions)
  • are not on insulin

More information (PDF, 76KB)

Consent Form (PDF, 350KB)

A Randomized, Multi-center, Double-blind, Placebo-controlled, Parallel-group Comparison, Phase 2a Study to Evaluate the Safety, Tolerability and Efficacy of SCO-792 in Subjects with Type 2 Diabetes and Albuminuria

You are eligible if you :

  • are aged 18-75 years
  • are able to participate in a study for up to 17 weeks
  • are receiving stable treatment for your diabetes and diabetic kidney disease for the past 3 months

More information (PDF, 172KB)

Consent Form (PDF, 305KB)

Comparative Persistence With Prolia and Weekly Alendronate in 6 Asia-Pacific countries: a Prospective Observational Study

You are eligible if you:

  • are a Post Menopausal Female with Osteoporosis
  • take Prolia (Denosumab) or Alendronate (Fosamax)

More information and Consent Form (PDF, 232KB)

The Effect of Tirzepatide versus Dulaglutide on Major Adverse Cardiovascular Events in Patients with Type 2 Diabetes (SURPASS-CVOT)

You are eligible if you:
• are at least 40 years of age
• have been diagnosed with type 2 diabetes
• have an established cardiovascular disease (coronary artery disease, cerebrovascular disease, or peripheral arterial disease).

More information (PDF, 793KB)

Consent Form (PDF, 306KB)